Comparison of Intradermal and Subcutaneous Routes of Cholera Vaccine Administration

McBean, A. Marshall; Compaore, Pierre; Agle, AndrewN.; Foster, S. O.; Mccormack, WilliamM.

doi:10.1016/s0140-6736(72)90187-0

Cited by 14 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These experiences included vaccination against measles, 39 , 40 cholera, 41 rabies, 42 , 43 hepatitis B 44 - 47 and poliomyelitis 48 - 51 . During the last century several clinical trials have been performed to evaluate the safety, tolerability and immunogenicity of intradermal administered influenza vaccines, but the absence of a consistent clinical design and standardized investigational method have not allowed efficient and significant comparisons and meta-analyses 52 - 63 .…”

Section: New Devices For Intradermal Vaccine Administration and Overvmentioning

confidence: 99%

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Icardi

Orsi

Ceravolo

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults <60 y and elderly people and post-marketing surveillance demonstrate that actually, licensed intradermal influenza vaccines, Intanza™ 9 and 15 µg and Fluzone™ Intradermal, administered by the microinjection system Soluvia™, show an excellent acceptability, tolerability and safety profile. Formulations containing 9 and 15 μg per strain demonstrate, respectively, comparable and superior immunogenicity than conventional intramuscular vaccines. Licensed intradermal influenza vaccines can be considered a valid alternative to standard intramuscular vaccination offering significant advantages in low-responder populations and helping to increase influenza vaccination coverage rates especially in people with fear of needles or high apprehension associated with annual vaccination.

show abstract